Abstract: The present invention provides methods and compositions for determining whether a subject would benefit from co-receptor inhibitor therapy. In certain aspects, the methods can be used to determine whether a subject infected with a dual-mixed tropic population of HIV would benefit from CCCR5-inhibitor therapy or CXCR4-inhibitor therapy, the methods comprising determining whether the HIV population is a homogeneous or heterogeneous population of HIV, wherein the nature of the homogenous or heterogenous population of HIV indicates whether the patient would benefit from co-receptor inhibitor therapy.
Type:
Grant
Filed:
February 26, 2008
Date of Patent:
February 28, 2017
Assignee:
LABORATORY CORPORATION OF AMERICA HOLDINGS
Abstract: The present invention provides an internal positive control for contaminating viruses. The invention provides the use of a second virus as an exogenous internal positive control in methods for verifying the reliability of an assay to detect a first virus, in methods of ensuring the absence of the first virus in a biological sample or pharmaceutical sample and in methods of manufacturing a vaccine free from a first virus.
Abstract: Reactive and modified M13 bacteriophages, and methods of making and using the same, are generally provided. The reactive M13 bacteriophage can include a alkyne functional group covalently attached to the M13 bacteriophage. The modified M13 bacteriophage can include a substituent covalently attached to the M13 bacteriophage via a 1,2,3-triazole linkage. Dual-modified M13 bacteriophages are also generally provided, and can include a cancer-targeting substituent covalently attached to the M13 bacteriophage and a fluorescent group covalently attached to the M13 bacteriophage. The modified M13 bacteriophages can not only be employed as a fluorescent probe for cancer imaging, but also can be used as biomaterials for cell alignment and scaffolding.
Abstract: The invention relates generally to the field of virology. More particularly, the present invention relates to methods for determining the effect of a viral inactivation procedure on the antigenicity of the inactivated virus, in particular, for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular, for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). The invention further provides methods to determine the antigenicity of an inactivated virus as well as methods to screen for anti-viral compounds using any one of the aforementioned methods. Methods of using the inactivated and immunogenic virus thus obtained, in particular, in the manufacture of a vaccine, are also provided by the present invention.
Type:
Grant
Filed:
February 27, 2009
Date of Patent:
January 17, 2017
Assignee:
Universiteit Gent
Inventors:
Peter Delputte, Hans Nauwynck, Iris Delrue, Merijn Vanhee
Abstract: The invention provides methods for the identification of patients capable of controlling HIV progression, as well as to the identification of an antagonist form of IP-10 associated to HIV progression control and the uses thereof for improving the immunological response of HIV patients.
Type:
Grant
Filed:
February 28, 2014
Date of Patent:
December 20, 2016
Assignee:
INSTITUT PASTEUR
Inventors:
Michaela Müller-Trutwin, Mickaël J. Y. Ploquin, Matthew Albert, Yoann Madec, Cécile Goujard, Laurence Meyer
Abstract: The invention relates to a method for the in vitro diagnostic detection of an infection with a microorganism, comprising placing a biological sample, in a single assay receptacle, in the presence of particles, each carrying at least one specific detectable physical parameter, and belonging to at least two different groups, one of the groups carrying an anti-IgM capture antibody and the other group carrying a capture antigen derived from said microorganism.
Abstract: The present invention provides safe, stable, efficacious, and cost-effective vaccines based on viral expression vectors that include a parainfluenza virus 5 (PIV5) genome including a heterologous nucleotide sequence expressing a heterologous polypeptide. In some embodiments, the heterologous nucleotide sequence is inserted closer to the leader than between the hemagglutinin-neuroaminidase (HN) gene and the large RNA polymerase protein (L) gene of the PIV5 genome. In some embodiments, the heterologous nucleotide sequence is inserted between the small hydrophobic protein (SH) gene and the hemagglutinin-neuroaminidase (HN) gene of the PIV 5 genome.
Type:
Grant
Filed:
January 24, 2013
Date of Patent:
November 29, 2016
Assignee:
University of Georgia Research Foundation, Inc.
Abstract: The object of the invention is a DNA vaccine, method of inducing the immune response, antibodies specifically recognizing the haemagglutinin H5 of an influenza virus and application of the DNA vaccine. According to the invention, one or two-fold immunization of hens with DNA vaccine containing a cDNA encoding the modified H5 haemagglutinin HA protein, i.e. with the deletion of the cleavage site between HA subunits (this provides for greater safety of the vaccines). Moreover, the encoding region of the HA is modified in such a way that protein production in the bird cells should achieve maximal yield. The main modification is codon optimization for the hens and deletion of the site of proteolytic cleavage between subunits HA1 and HA2.
Type:
Grant
Filed:
September 21, 2012
Date of Patent:
November 29, 2016
Assignee:
INSTYTUT BIOCHEMII I BIOFIZYKI PAN
Inventors:
Agnieszka Sirko, Anna Góra-Sochacka, Włodzimierz Zagórski-Ostoja, Anna Stachyra, Róza Sawicka, Bogusław Szewczyk, Beata Gromadzka, Violetta Sączyńska, Katarzyna Florys, Zenon Minta, Krzysztof Śmietanka
Abstract: Disclosed herein are isolated immunogens including variant hepatitis B surface antigens (HBsAgs). In an example, a variant HBsAg includes a HBsAg with one or more transmembrane domains of the HBsAg replaced with a gp41 antigenic insert. The antigenic insert can include an antigenic polypeptide fragment of gp41 including the membrane proximal region of gp41 and a transmembrane membrane region of gp41. The replacement of a membrane spanning domain of HBsAg with a membrane spanning domain of gp41 anchors gp41 into HBsAg in virtually the identical orientation as on HIV virions and correctly orients the nearby MPR on the lipid layer. Thus, the disclosed variant HBsAgs display the neutralization-sensitive MPR in association with a lipid layer, while presenting it at the most immunogenic site on HBsAg. Also disclosed are uses of these variant HBsAgs, and nucleic acids encoding variant HBsAgs, such as to induce an immune response to HIV-1.
Type:
Grant
Filed:
March 9, 2015
Date of Patent:
November 8, 2016
Assignee:
The United States of America, as represented by the Secretary of the Department of Health and Human Services
Abstract: Provided herein is a method of detecting the presence of influenza virus in a sample while minimizing false positives due to presence of one or more other pathogens in the sample, the method including measuring the enzymatic activity of neuraminidase (NA) in the sample under one or more differentiating conditions selected from the group consisting of pH, binding to anti-NanA antibody, size exclusion, hemagglutinin (HA) binding, chemical inhibition, and combinations thereof.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
November 8, 2016
Assignee:
University of Cincinnati
Inventors:
Alison A. Weiss, Karen Melissa Gallegos Villalobos
Abstract: A composition comprising the following composition: an AD vehicle including a synthetic peptide and a lipid, wherein the synthetic peptide includes the amino acid sequence KnLm (wherein n is 4 to 8 and m is 11 to 20), a carboxylvinyl polymer and an RSV antigen. The composition has an antibody producing ability which is further higher than that of a conventional mucosal vaccine, hence capable of exerting excellent anti-virus antigen-specific IgA antibody- and IgG antibody-inducing effect in the nasal wash and the serum, respectively, even with an extremely small quantity of an RSV antigen.
Type:
Grant
Filed:
August 29, 2012
Date of Patent:
October 11, 2016
Assignee:
TOKUSHIMA UNIVERSITY
Inventors:
Hiroshi Kido, Dai Mizuno, Hirotsugu Ueda, Koji Yoshikawa, Keisuke Ohsumi, Nobuyuki Yamamoto, Kenji Sudo
Abstract: The present invention provides a method for conveniently producing a protein formulation in which viruses are inactivated, without impairing the quality of the obtained protein formulation, characterized by including the step of exposing the protein formulation contaminated with the viruses to a 0.1-2M aqueous solution of arginine, an arginine derivative, or a mixture thereof, the aqueous solution being adjusted to pH 3.5 to 5. The present invention also provides a virus inactivation method characterized by including the step of contacting a virus-containing object with a 0.1-2M aqueous solution of arginine, an arginine derivative, or a mixture thereof, the aqueous solution being adjusted to pH 3.5 to 5.
Abstract: The invention relates to a method for producing a modified viral strain of a virus which is a member of the Reoviridae family and, in particular, relates to vaccinal viral strains of the Orbivirus genus.
Type:
Grant
Filed:
January 28, 2014
Date of Patent:
October 4, 2016
Assignee:
London School of Hygiene and Tropical Medicine
Abstract: The present invention provides an immunogenic influenza composition in a dose volume suitable for human use, comprising an influenza virus antigen or antigenic preparation thereof and an adjuvant composition comprising an oil-in-water emulsion, wherein said oil-in-water emulsion comprises a metabolisable oil at a level of below 11 mg and an emulsifying agent at a level of below 5 mg and optionally a tocol or a sterol at a level of below 12 mg. Suitably the amount of influenza antigen per strain per dose is 15 ?g HA or a low amount such as less than 15 ?g HA.
Type:
Grant
Filed:
April 15, 2008
Date of Patent:
September 27, 2016
Assignee:
GLAXOSMITHKLINE BIOLOGICALS SA
Inventors:
William Ripley Ballou, Emmanuel Jules Hanon
Abstract: The invention relates to antibodies and subsequences thereof that specifically bind to poxvirus B5R envelope protein, antibodies and subsequences thereof that specifically bind to poxvirus H3L envelope protein, and combinations thereof.
Type:
Grant
Filed:
December 27, 2013
Date of Patent:
September 20, 2016
Assignees:
KYOWA HAKKO KIRIN CO., LTD., LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
Abstract: The present invention provides Rotavirus antigenic polypeptides or antigens that elicit an immune response in animal or human against rotavirus, compositions comprising said rotavirus polypeptides, methods of vaccination against rotavirus, and kits for use with such methods and compositions. The invention further provide novel expression vectors for producing the vaccine antigenic polypeptides.
Type:
Grant
Filed:
February 14, 2013
Date of Patent:
September 20, 2016
Assignee:
Merial, Inc.
Inventors:
Russell F. Bey, Randy S Simonson, Kamesh Reddy Sirigireddy, Benjamin Matthew Hause
Abstract: Described is a chimerical adenovirus-parvovirus vector characterized in that it comprises the entire parvovirus genome inserted into a adenovirus genome, wherein: (a) the adenovirus genome is characterized by deletion of E1 and E3, and (b) the biological activity of the parvoviral protein NS, preferably NS1, is reduced or eliminated.
Type:
Grant
Filed:
January 6, 2014
Date of Patent:
September 13, 2016
Assignee:
DEUTSCHES KREBSFORSCHUNGSZENTRUM
Inventors:
Nazim El-Andaloussi, Antonio Marchini, Jean Rommelaere
Abstract: Methods and systems for purifying cells and/or viruses are provided. The sample is added to a well disposed in a medium. A potential is applied across the medium to cause the contaminants to enter one or more walls of the well, and retain the cells and/or viruses in the well. The cells and/or viruses can be removed from the well, and optionally adhered or fixed to a surface, or detected. In one embodiment, the cells and/or viruses may be retained in the well by embedding in the medium. The medium including the embedded cells and/or viruses may be excised or otherwise removed and transferred to a glass slide or other solid surface.
Type:
Grant
Filed:
March 7, 2012
Date of Patent:
September 6, 2016
Assignee:
ACCELERATE DIAGNOSTICS, INC.
Inventors:
Steven W. Metzger, Kenneth Robert Hance
Abstract: The document provides nucleic acids, polypeptides, and viruses containing nucleic acids and/or polypeptides. The document also provides methods for using viruses to treat cancer patients. Specifically, the document provides nucleic acid molecules encoding viral hemagglutinin (H) polypeptides, viral H polypeptides, and viruses containing nucleic acids and/or H polypeptides. Such viruses are useful for vaccinations and for treating cancer patients as the viruses are not shed.
Type:
Grant
Filed:
April 10, 2014
Date of Patent:
September 6, 2016
Assignee:
Mayo Foundation for Medical Education and Research
Inventors:
Roberto Cattaneo, Vincent H. J. Leonard
Abstract: The present invention relates to a method of designing an inhibitor of the binding of HIV (human immunodeficiency virus) glycoprotein (gp)120 to a CD4-receptor or to the integrin alpha4 beta7 (a4b7). The inhibitor interacts with at least two amino acid residues comprised in six motifs within the 3-dimensional structure of gp120. Also provided are compounds, pharmaceutical compositions thereof and uses thereof in the development of an inhibitor of the binding of a HIV gp120 to a CD4-receptor or an integrin alpha4 beta7 (a4b7). The inhibitors are useful for the prevention or treatment of an HIV infection and/or diseases associated with an HIV infection.
Type:
Grant
Filed:
October 27, 2011
Date of Patent:
August 23, 2016
Assignee:
KFLP BIOTECH, LLC
Inventors:
Andrey Vinnik, Peter Fedichev, Maxim Kholin, Christopher Molloy, Aron Katz